Merck & Co Inc 

MRK:NYSE

LastChange / % ChangeDividend YieldVolumeAvg Volume (10 day)
46.75 -0.54   -1.14%3.64%20,674,52315.8M

Market data is delayed by at least 20 minutes.
Market is closed. As of 03:59 PM ET 10/14/2013
 
 
 

Latest News Headlines for Merck & Co Inc

Results of Phase II PRECEDENT Trial for Investigational Folate Receptor Therapy Vintafolide in Patients with Platinum-Resistant Ovarian Cancer Published in Journal of Clinical Oncology
2 hours 41 minutes ago - BusinessWire via Dow Jones News
Merck and Endocyte's Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--October 14, 2013-- Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online publication of results from the randomized Phase II PRECEDENT trial for vintafolide (MK-8109/EC145), an investigational folate small molecule drug conjugate (SMDC), in the Journal of Clinical Oncology (JCO), the official journal of the American Society of Clinical Oncology. These trial results are the basis for the vintafolide regulatory application currently under review with the European Medicines Agency for the treatment of folate-receptor positive platinum-resistant ovarian cancer in combination with pegylated liposomal doxorubicin (PLD). Enrollment is ongoing in the pivotal Phase III PROCEED clinical trial with vintafolide, along with investigational companion imaging agent etarfolatide (EC20), in platinum-resistant ovarian cancer (Clinicaltrials.gov NCT01170650).
Results of Phase II PRECEDENT Trial for -2-
2 hours 41 minutes ago - BusinessWire via Dow Jones News
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
View more recent headlines
 
 
 
 
 
 
More Filings

Latest Annual and Quarterly SEC Filings

10-K
February 28, 2013
This report contains detailed information about the company's business finances and management.
10-Q
August 7, 2013
Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)
 
 
 
Company Background
Merck & Co., Inc. (Merck) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company consists of four operating segments, which are the Pharmaceutical, Animal Health, Consumer Care and Alliances segments, and one reportable segment, which is the Pharmaceutical segment. The Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Effective February 25, 2013, Dashtag, a unit of Merck & Co Inc's Schering Plough Corp subsidiary acquired 17.95% interest in Fulford (India) Ltd.

Bid/Size
-- / --
Ask/Size
-- / --
Price Open
46.80
Previous Close
47.29
Day High
47.08
Day Low
46.44
52wk High/Date
50.16 / 6/4/2013
52wk Low/Date
40.02 / 12/31/2012
% off 52wk High
-6.80%
% off 52wk Low
16.82%
Beta (5 Yr)
0.6
Market Capitalization
136.8B
Shares Outstanding
2.9B
Volatility Avg
17.27
EPS(TTM)
1.68
P/E Ratio
27.8
Dividend Announcement
7/24/2013
Dividend Yield
3.64%
Ex-Date
9/12/2013
Date of Record
9/16/2013
Payable
0.43 - QRTR
Payable Date
10/7/2013
Last Trade as of 10/14/2013 4:00 PM ET
 
 
 

MRK Merck & Co Inc vs. Peers

Peers 
MRK
Merck & Co Inc
15.51%
Johnson & Johnson
27.60%
Pfizer Inc.
14.52%
Abbott Laboratories
7.72%
Eli Lilly & Co.
-0.89%
MRK
Merck & Co Inc
3.68%
Johnson & Johnson
2.95%
Pfizer Inc.
3.34%
Abbott Laboratories
1.66%
Eli Lilly & Co.
4.01%
MRK
Merck & Co Inc
-1.14%
Johnson & Johnson
0.39%
Pfizer Inc.
2.19%
Abbott Laboratories
0.71%
Eli Lilly & Co.
0.31%
Compare these stocks